Reversing EGFR Mediated Immunoescape by Targeted Monoclonal Antibody Therapy
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Reversing EGFR Mediated Immunoescape by Targeted Monoclonal Antibody Therapy
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 8, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2017-05-30
DOI
10.3389/fphar.2017.00332
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- EGFR Signaling Enhances Aerobic Glycolysis in Triple-Negative Breast Cancer Cells to Promote Tumor Growth and Immune Escape
- (2016) S.-O. Lim et al. CANCER RESEARCH
- Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients
- (2016) S. Trivedi et al. CLINICAL CANCER RESEARCH
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
- (2016) Chia-Wei Li et al. Nature Communications
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- CTLA-4+Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis
- (2015) Hyun-Bae Jie et al. CANCER RESEARCH
- Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFN That Induce PD-L1 Expression in Head and Neck Cancer
- (2015) F. Concha-Benavente et al. CANCER RESEARCH
- Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial
- (2015) Ricard Mesía et al. LANCET ONCOLOGY
- Comparison of uncommon EGFR exon 21 L858R compound mutations with single mutation
- (2015) Shunchang Jiao et al. OncoTargets and Therapy
- Tumor-induced perturbations of cytokines and immune cell networks
- (2014) Brett Burkholder et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Epidermal Growth Factor Receptor (EGFR) Signaling Regulates Global Metabolic Pathways in EGFR-mutated Lung Adenocarcinoma
- (2014) Hideki Makinoshima et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- EGFR-mediated tumor immunoescape
- (2014) Fernando Concha-Benavente et al. OncoImmunology
- Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma
- (2013) S. Lyford-Pike et al. CANCER RESEARCH
- SHP2 Is Overexpressed and Inhibits pSTAT1-Mediated APM Component Expression, T-cell Attracting Chemokine Secretion, and CTL Recognition in Head and Neck Cancer Cells
- (2013) M. S. Leibowitz et al. CLINICAL CANCER RESEARCH
- The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered
- (2013) Hui K. Gan et al. FEBS Journal
- Mutation frequency in 15 common cancer genes in high-risk head and neck squamous cell carcinoma
- (2013) Sean M. McBride et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor–Resistant Disease
- (2013) Kadoaki Ohashi et al. JOURNAL OF CLINICAL ONCOLOGY
- Cetuximab Reverses the Warburg Effect by Inhibiting HIF-1-Regulated LDH-A
- (2013) H. Lu et al. MOLECULAR CANCER THERAPEUTICS
- Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
- (2013) E. A. Akbay et al. Cancer Discovery
- Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate
- (2012) Patrick S. Ward et al. CANCER CELL
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Natural killer (NK):dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity
- (2011) Steve C. Lee et al. IMMUNOLOGIC RESEARCH
- The Mutational Landscape of Head and Neck Squamous Cell Carcinoma
- (2011) N. Stransky et al. SCIENCE
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- Putative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patients
- (2010) Raphaël Maréchal et al. BMC CANCER
- Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells
- (2009) Andrés López-Albaitero et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Gamma interferon-mediated superinduction of B7-H1 in PTEN-deficient glioblastoma: a paradoxical mechanism of immune evasion
- (2009) Seunggu J. Han et al. NEUROREPORT
- FcγRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck
- (2008) Rodney J. Taylor et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- The epidermal growth factor receptor family: Biology driving targeted therapeutics
- (2008) M. J. Wieduwilt et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Enhanced T-Cell Responses to Glioma Cells Coated With the Anti-EGF Receptor Antibody and Targeted to Activating Fc??Rs on Human Dendritic Cells
- (2008) Devi Banerjee et al. JOURNAL OF IMMUNOTHERAPY
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
- (2008) Jan B. Vermorken et al. NEW ENGLAND JOURNAL OF MEDICINE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started